BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

496 related articles for article (PubMed ID: 26969876)

  • 21. TERT promoter mutations and long-term survival in patients with thyroid cancer.
    Kim TH; Kim YE; Ahn S; Kim JY; Ki CS; Oh YL; Kim K; Yun JW; Park WY; Choe JH; Kim JH; Kim JS; Kim SW; Chung JH
    Endocr Relat Cancer; 2016 Oct; 23(10):813-23. PubMed ID: 27528624
    [TBL] [Abstract][Full Text] [Related]  

  • 22. BRAF and TERT promoter mutations in the aggressiveness of papillary thyroid carcinoma: a study of 653 patients.
    Jin L; Chen E; Dong S; Cai Y; Zhang X; Zhou Y; Zeng R; Yang F; Pan C; Liu Y; Wu W; Xing M; Zhang X; Wang O
    Oncotarget; 2016 Apr; 7(14):18346-55. PubMed ID: 26943032
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Role of molecular markers to predict distant metastasis in papillary thyroid carcinoma: Promising value of TERT promoter mutations and insignificant role of BRAF mutations-a meta-analysis.
    Vuong HG; Altibi AM; Duong UN; Ngo HT; Pham TQ; Tran HM; Oishi N; Mochizuki K; Nakazawa T; Hassell L; Katoh R; Kondo T
    Tumour Biol; 2017 Oct; 39(10):1010428317713913. PubMed ID: 29037127
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of BRAF V600E and TERT Promoter Mutations on Response to Therapy in Papillary Thyroid Cancer.
    Trybek T; Walczyk A; Gąsior-Perczak D; Pałyga I; Mikina E; Kowalik A; Hińcza K; Kopczyński J; Chrapek M; Góźdź S; Kowalska A
    Endocrinology; 2019 Oct; 160(10):2328-2338. PubMed ID: 31305897
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of BRAF
    Mu ZZ; Zhang YQ; Sun D; Lu T; Lin YS
    Endocr Pract; 2022 Mar; 28(3):265-270. PubMed ID: 34890787
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association between TERT promoter mutations and clinical behaviors in differentiated thyroid carcinoma: a systematic review and meta-analysis.
    Yang J; Gong Y; Yan S; Chen H; Qin S; Gong R
    Endocrine; 2020 Jan; 67(1):44-57. PubMed ID: 31655978
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic significance of TERT promoter and BRAF mutations in TIR-4 and TIR-5 thyroid cytology.
    Censi S; Barollo S; Grespan E; Watutantrige-Fernando S; Manso J; Iacobone M; Casal Ide E; Galuppini F; Fassina A; Bertazza L; Vianello F; Pennelli G; Mian C
    Eur J Endocrinol; 2019 Jul; 181(1):1-11. PubMed ID: 31042674
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association of TERT Promoter Mutation, But Not BRAF Mutation, With Increased Mortality in PTC.
    George JR; Henderson YC; Williams MD; Roberts DB; Hei H; Lai SY; Clayman GL
    J Clin Endocrinol Metab; 2015 Dec; 100(12):E1550-9. PubMed ID: 26461266
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genomic characterization of high-recurrence risk papillary thyroid carcinoma in a southern Chinese population.
    Li M; Jia H; Qian Q; Wen P; Chen C; Hua Y; Wang K; Zhang W; Shi F
    Diagn Pathol; 2020 May; 15(1):49. PubMed ID: 32393293
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Uncommon TERT Promoter Mutations in Pediatric Thyroid Cancer.
    Alzahrani AS; Qasem E; Murugan AK; Al-Hindi HN; AlKhafaji D; Almohanna M; Xing M; Alhomaidah D; AlSwailem M
    Thyroid; 2016 Feb; 26(2):235-41. PubMed ID: 26711586
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Changes in the clinicopathological characteristics and genetic alterations of follicular thyroid cancer.
    Song YS; Lim JA; Min HS; Kim MJ; Choi HS; Cho SW; Moon JH; Yi KH; Park DJ; Cho BY; Park YJ
    Eur J Endocrinol; 2017 Dec; 177(6):465-473. PubMed ID: 28864536
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Coexistence of
    Rusinek D; Pfeifer A; Krajewska J; Oczko-Wojciechowska M; Handkiewicz-Junak D; Pawlaczek A; Zebracka-Gala J; Kowalska M; Cyplinska R; Zembala-Nozynska E; Chekan M; Chmielik E; Kropinska A; Lamch R; Jurecka-Lubieniecka B; Jarzab B; Czarniecka A
    Int J Mol Sci; 2018 Sep; 19(9):. PubMed ID: 30200646
    [No Abstract]   [Full Text] [Related]  

  • 33. Identification of somatic TERT promoter mutations in familial nonmedullary thyroid carcinomas.
    Marques IJ; Moura MM; Cabrera R; Pinto AE; Simões-Pereira J; Santos C; Menezes FD; Montezuma D; Henrique R; Rodrigues Teixeira M; Leite V; Cavaco BM
    Clin Endocrinol (Oxf); 2017 Oct; 87(4):394-399. PubMed ID: 28502101
    [TBL] [Abstract][Full Text] [Related]  

  • 34. TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas.
    Melo M; da Rocha AG; Vinagre J; Batista R; Peixoto J; Tavares C; Celestino R; Almeida A; Salgado C; Eloy C; Castro P; Prazeres H; Lima J; Amaro T; Lobo C; Martins MJ; Moura M; Cavaco B; Leite V; Cameselle-Teijeiro JM; Carrilho F; Carvalheiro M; Máximo V; Sobrinho-Simões M; Soares P
    J Clin Endocrinol Metab; 2014 May; 99(5):E754-65. PubMed ID: 24476079
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dissecting Anaplastic Thyroid Carcinoma: A Comprehensive Clinical, Histologic, Immunophenotypic, and Molecular Study of 360 Cases.
    Xu B; Fuchs T; Dogan S; Landa I; Katabi N; Fagin JA; Tuttle RM; Sherman E; Gill AJ; Ghossein R
    Thyroid; 2020 Oct; 30(10):1505-1517. PubMed ID: 32284020
    [No Abstract]   [Full Text] [Related]  

  • 36. Refining Dynamic Risk Stratification and Prognostic Groups for Differentiated Thyroid Cancer With TERT Promoter Mutations.
    Kim TH; Ki CS; Kim HS; Kim K; Choe JH; Kim JH; Kim JS; Oh YL; Hahn SY; Shin JH; Jang HW; Kim SW; Chung JH
    J Clin Endocrinol Metab; 2017 May; 102(5):1757-1764. PubMed ID: 28323925
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Facilitation of Definitive Cancer Diagnosis With Quantitative Molecular Assays of BRAF V600E and TERT Promoter Variants in Patients With Thyroid Nodules.
    Fu G; Chazen RS; Monteiro E; Vescan A; Freeman JL; Witterick IJ; MacMillan C
    JAMA Netw Open; 2023 Jul; 6(7):e2323500. PubMed ID: 37505499
    [TBL] [Abstract][Full Text] [Related]  

  • 38. TERT Promoter Mutations in Thyroid Cancer.
    Alzahrani AS; Alsaadi R; Murugan AK; Sadiq BB
    Horm Cancer; 2016 Jun; 7(3):165-77. PubMed ID: 26902827
    [TBL] [Abstract][Full Text] [Related]  

  • 39. TERT promoter Mutation and Its Association with Clinicopathological Features and Prognosis of Papillary Thyroid Cancer: A Meta-analysis.
    Liu C; Liu Z; Chen T; Zeng W; Guo Y; Huang T
    Sci Rep; 2016 Nov; 6():36990. PubMed ID: 27833153
    [TBL] [Abstract][Full Text] [Related]  

  • 40. TERT promoter mutations and Ki-67 labeling index as a prognostic marker of papillary thyroid carcinomas: combination of two independent factors.
    Matsuse M; Yabuta T; Saenko V; Hirokawa M; Nishihara E; Suzuki K; Yamashita S; Miyauchi A; Mitsutake N
    Sci Rep; 2017 Feb; 7():41752. PubMed ID: 28150740
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.